A Life Less Injected: New Drug Offers Hope for Acromegaly Patients

SOUTH SAN FRANCISCO, Calif. – June 15, 2026 – For the thousands of people living with acromegaly, life is often measured in injections. It’s a routine of needles, schedules, and the constant, underlying anxiety of a chronic disease that never truly sleeps. But new data from a small biotech firm suggests a future where that routine could be profoundly different. Marea Therapeutics has presented early clinical trial results for a new drug, MAR002, that not only shows promise for better disease control but could potentially replace daily or monthly injections with a dose administered just once every two weeks, or even monthly.

For patients and physicians who have long battled the limitations of existing therapies, this news, presented at the 2026 Annual Meeting of the Endocrine Society (ENDO), represents more than just a scientific update; it’s a significant glimmer of hope.

The Unseen Burden of Acromegaly

Acromegaly is a cruel and insidious disease. Caused most often by a benign tumor on the pituitary gland, it floods the body with excess growth hormone (GH), leading to abnormally high levels of insulin-like growth factor-1 (IGF-1). The results are often visible—the gradual enlargement of hands, feet, and facial features—but the most dangerous consequences are internal. If left unchecked, it can lead to severe complications including cardiovascular disease, diabetes, and a shortened lifespan.

Treatment is a multi-step, often lifelong, battle. Surgery to remove the tumor is the first line of defense, but it isn’t always a complete cure. For the roughly 50% of patients who require further medical intervention, the options come with significant trade-offs. The current mainstays are somatostatin receptor ligands (SRLs), typically administered as painful monthly injections, and the growth hormone receptor antagonist (GHRA) pegvisomant, which is highly effective at lowering IGF-1 but requires daily self-injections.

This relentless treatment regimen creates a heavy burden. Patients plan their lives, travel, and work around injection schedules. Adherence can be a struggle, and the real-world efficacy of a drug that sits in its vial is zero. More critically, even with these demanding treatments, a large portion of patients still don't achieve optimal disease control. “Acromegaly remains a disorder of significant unmet need, with fewer than 35% of patients achieving optimal disease control on first-line medical therapy,” said Shlomo Melmed M.D., Distinguished Professor and Dean at Cedars-Sinai, in a statement responding to the new data. This gap between the available tools and the desired outcome is where the need for innovation becomes a human rights issue—the right to a life less defined by disease.

A New Mechanism, A New Promise

This is the landscape into which Marea Therapeutics has introduced MAR002. Described as a first-in-class allosteric monoclonal antibody, it works by targeting the growth hormone receptor in a novel way, effectively blocking the signal that leads to excess IGF-1 production. The company’s first-in-human Phase 1 study, while small and conducted in healthy volunteers, provided what its developers call compelling evidence that this approach works.

The data showed that single doses of MAR002 were safe and well-tolerated, with no serious adverse events. More importantly, the drug led to a robust and durable reduction in IGF-1 levels, with up to 64% peak suppression. This figure immediately caught the attention of experts. “The depth of initial IGF-1 suppression reported with MAR002 of up to 64% is particularly notable, as it appears to exceed levels seen with previously reported therapies in acromegaly,” Dr. Melmed noted.

For Marea, this is a powerful validation of their scientific platform, which leverages advances in human genetics to develop targeted medicines for cardioendocrine diseases. “The Phase 1 data presented at ENDO provide compelling proof-of-mechanism for MAR002 and strengthen our confidence as we advance into a Phase 2/3 study in patients with acromegaly expected to begin in the coming weeks,” said Rebecca Juliano, Ph.D., the company’s chief development officer. By directly blocking growth hormone signaling, she explained, MAR002 “has the potential to deliver meaningful biochemical control for a broad population of patients and establish a new standard of care in acromegaly.”

Redefining Treatment: From Efficacy to Quality of Life

While the impressive IGF-1 suppression numbers are scientifically significant, the true revolution of MAR002 may lie in its potential to change the daily reality of patients. The drug’s pharmacokinetic profile—how it is absorbed, distributed, and eliminated by the body—suggests it has a long duration of action, a characteristic that could support dosing as infrequently as every two weeks to once a month.

This is a paradigm shift. Moving from 365 injections a year with the current GHRA to just 12 or 26 would be transformative. It would reduce the physical and psychological burden of treatment, improve adherence, and untether patients from a demanding daily or monthly ritual. It would allow them to travel more freely, feel more “normal,” and focus less on the mechanics of their illness and more on the business of living.

This potential for a “best-in-disease” profile, as the company claims, is built on this dual promise: superior biochemical control combined with vastly improved convenience. For a community that has long balanced the benefits of treatment against its burdens, a drug that offers to maximize the former while minimizing the latter could fundamentally reshape the acromegaly market and, more importantly, the lives of those affected by it.

The Long Road Ahead

Of course, the road from a promising Phase 1 trial to a pharmacy shelf is long and fraught with uncertainty. The initial study was in healthy volunteers, not the target patient population. The upcoming Phase 2/3 study will be the true test, where MAR002 must prove it is both safe and effective in people actually living with acromegaly over a longer period. The competitive landscape is also evolving, with other companies pursuing novel approaches, including oral medications, to address the same unmet needs.

Still, the data presented by Marea Therapeutics marks a moment of tangible optimism. It is a testament to a strategic approach focused on solving difficult problems in cardioendocrine disease, a field where the company is also advancing another drug, MAR001, for severe hypertriglyceridemia. For now, the successful Phase 1 results for MAR002 provide a powerful new narrative of what the future could hold for acromegaly patients—a future with better control, greater freedom, and a life less punctuated by the point of a needle.